Stem Cell Study for Patients With Heart Disease

Inclusion Criteria: * Subjects with functional class (CCS) III or IV angina. * Subjects who have attempted "best" medical therapy without control of symptoms. * All subjects must have a recent coronary angiogram (within the last 3 months). * Clinical signs and symptoms of clinically significant ischemia on nuclear perfusion imaging. * Subjects must be able to complete a minimum of 1 minute but no more than 6 minutes of the Standard Bruce Protocol. * Subject experiences angina during the baseline exercise tolerance test. * Subjects must either be no longer capable of reproduction or taking acceptable measures to prevent reproduction during the study. * Normal renal function. * Normal liver function. * Normal blood count. Angiographic Inclusions: * Total occlusion of an epicardial coronary artery. * Candidates at high risk for percutaneous coronary angioplasty of treatment zone(s) based upon clinical or anatomic considerations including but not limited to the following: diabetes, congestive heart failure (severe right heart failure, NYHA class III or IV), left main disease, pulmonary hypertension, severe proximal vessel tortuosity, severe bendpoint obstructions, diffuse disease (\>2 cm in length), small vessel (\<2 mm reference diameter), stenosis which are either diffuse (\>2 cm in length) or distal, incessant restenosis lesions, unfavorable bifurcation stenosis, and degenerated or thrombosed saphenous vein grafts. Exclusion Criteria: * Predominant congestive heart failure symptoms. * Patients who have been hospitalized with a primary diagnosis of CHF in the prior 6 months. * Patients who have had diuretics added to their medical regimen or an increase in diuretic dosage for signs or symptoms of CHF in the past 6 months. * Patients with a left ventricular ejection fraction of less than 25% as determined by transthoracic echocardiography. * Patients with physical findings consistent with ongoing uncontrolled CHF. * Myocardial infarction within 30 days of treatment. * Successful coronary revascularization procedures within 3 months of study enrollment. * Documented stroke or transient ischemic attack (TIA) within 60 days of study enrollment. * History of severe aortic stenosis or insufficiency; severe mitral stenosis; or severe mitral insufficiency. * Severe co-morbidity associated with a reduction in life expectancy of less than 1 year. * Subjects with PT, PTT or platelet counts greater than the upper limit of normal and those with a hematocrit \<35%. * Subjects with uncontrolled hypertension. * Currently enrolled in another investigational device or drug trial (IDE or IND) that has not completed the required follow-up period. * History of alcohol or drug abuse within 3 months of screening. * Joint or peripheral vascular disease that severely limits treadmill walking. * Chronic obstructive pulmonary disease that severely limits walking or FEV1.0\<30% predicted. * Subjects who are pregnant or lactating. * Males and females who are capable of reproduction and will not take acceptable measures to prevent reproduction during the study. * Subjects who test positive for HIV, hepatitis B or hepatitis C, have a chronic inflammatory disease, autoimmune disease or are on chronic immunosuppressive medications. * Subjects with a known hypersensitivity to E. coli-derived proteins. * Subjects with evidence (clinical, laboratory, or imaging) of cancer recurrence within the past 5 years (other than non-melanoma skin cancer or in situ cervical carcinoma).